We have also studied the risk of CRC in groups with ‘intermediate’ f-Hb, defined as the range of f-Hb between various chosen reassurance thresholds and a threshold to trigger urgent investigation where PPV for CRC was ≥3%.11 This evidence concerns the gene GSTM1 and colorectal carcinoma.